This study looks at how well two cancer drugs, **datopotamab deruxtecan (Dato-DXd)** and **pembrolizumab**, work alone and with **platinum chemotherapy** for treating a type of lung cancer called **non-small cell lung cancer (NSCLC)**. It is for people who haven't had treatment for advanced or metastatic NSCLC before. **Metastatic** means the cancer has spread to other parts of the body.
The main goals are to see how long patients live without the cancer growing (called **Progression-Free Survival, PFS**) and how long they live overall (called **Overall Survival, OS**). Patients will be randomly put into one of three groups to get different treatments. The study includes a **Screening Period** to check eligibility, a **Treatment Period**, and a **Follow-up Period** to monitor health after treatment.
- The study involves three treatments: Dato-DXd with pembrolizumab, with or without platinum; or pembrolizumab with platinum and another drug called pemetrexed.
- Participants must be 18 or older and have specific lung cancer without certain genetic changes.
- Some restrictions include having no previous treatments for advanced NSCLC and no serious heart or immune system issues.